SCHEMBL26890664

SCHEMBL26890664

CC(C)(C)OC(=O)N1CCCn2nc(CO)c(Cl)c2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ CYBB P04839 1/20 0.38
▸ NOX5 Q96PH1 1/20 0.38
▸ NOX4 Q9NPH5 1/20 0.38
▸ NOX1 Q9Y5S8 1/20 0.38
▸ ESR2 Q92731 1/20 0.37
▸ NR1H2 P55055 3/20 0.36
▸ GRM5 P41594 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ SUV39H2 Q9H5I1 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ PREP P48147 1/20 0.35
▸ USP2 O75604 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CTSK P43235 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25434099 0.86 MEN1 (0.40) MEN1KMT2ACYBBNOX5NOX4
SCHEMBL30793319 0.86 MEN1 (0.37) MEN1KMT2ACYBBNOX5NOX4
SCHEMBL26890665 0.85 MEN1 (0.38) MEN1KMT2ACYBBNOX5NOX4
SCHEMBL25337280 0.82 NR1H2 (0.42) MEN1KMT2ACYBBNOX5NOX4
SCHEMBL25434412 0.82 POLB (0.40) MEN1KMT2AESR2SUV39H2POLB
SCHEMBL25335687 0.82 MEN1 (0.43) MEN1KMT2ACYBBNOX5NOX4
SCHEMBL26686738 0.82 MEN1 (0.43) MEN1KMT2ACYBBNOX5NOX4
SCHEMBL29464005 0.81 MEN1 (0.38) MEN1KMT2ACYBBNOX5NOX4
SCHEMBL26686561 0.81 HPGD (0.41) MEN1KMT2ACYBBNOX5NOX4
SCHEMBL26687047 0.80 ADORA1 (0.42) MEN1KMT2ACYBBNOX5NOX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912723-B2 KRAS modulators and uses thereof QUANTA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
US-20230374042-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374042-A1 KRAS MODULATORS AND USES THEREOF KRAS, NRAS, HRAS MEN1 551/4885KMT2A 2868/4885CYBB 3794/4885
US-11912723-B2 KRAS modulators and uses thereof KRAS, NRAS, HRAS MEN1 551/4885KMT2A 2868/4885CYBB 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback